NCT03011268 2025-05-31
BIOSTOP
Helse Møre og Romsdal HF
Phase NA Completed
Clinical Trials
32 trialsNCT05090124 2025-01-14
REALISE
NHS Greater Glasgow and Clyde
Phase NA Completed
NCT04009668 2024-10-30
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
University of Michigan
Phase 2 Completed
NCT03180957 2024-06-28
RIDD
University of Oxford
Phase 2 Completed
NCT05073315 2024-02-09
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Amgen
Phase 3 Completed
NCT04255134 2023-05-18
BIORA-PAIN
St George's, University of London
Phase 4 Completed
NCT04551352 2022-10-03
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
Phase 1 Completed
NCT04798287 2022-06-22
STAR-RA-Cancer
Brigham and Women's Hospital
Completed
NCT00837434 2021-09-22
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4 Completed
NCT02762955 2021-09-08
CALYPSO
Biocad
Phase 3 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT02163759 2021-07-23
HIBISCUS I
Hoffmann-La Roche
Phase 3 Completed
NCT02171429 2021-07-23
HIBISCUS II
Hoffmann-La Roche
Phase 3 Completed
NCT02492217 2020-11-03
Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients
Universidade Nova de Lisboa
Phase 4 Completed
NCT01060098 2020-01-18
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Imperial College London
Completed
NCT02778789 2019-09-26
Re-Bone
University of Erlangen-Nürnberg Medical School
Completed
NCT02912247 2019-03-07
Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT02499783 2019-01-04
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
AbbVie
Phase 3 Completed
NCT02893254 2018-06-04
Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT02196701 2018-03-19
CLEAR
AbbVie
Phase 3 Completed
NCT01635764 2018-01-24
PIONEER (OLE)
AbbVie
Phase 3 Completed
NCT02437253 2017-09-15
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase 1/2 Completed
NCT00932113 2017-08-31
MOA
Tufts Medical Center
Phase 4 Completed
NCT01295151 2016-11-02
SWITCH
University of Leeds
Phase 4 Completed
NCT00595413 2016-02-17
AUGUST II
EMD Serono
Phase 2 Completed
NCT02376478 2015-03-03
On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection
Medical University of Vienna
Completed
NCT00597623 2012-07-26
DORA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT00420927 2012-04-18
OPTIMA
Abbott
Phase 4 Completed
NCT01078571 2011-10-28
DALI
Abbott
Completed
NCT00085644 2011-04-21
ATLAS
Abbott
Phase 3 Completed
NCT00497614 2008-12-05
PETRA
University Hospital, Tours
Phase NA Completed
NCT00696059 2008-06-12
HURRAH
Hvidovre University Hospital
Phase 4 Completed